Anvisa approves two cannabis-based products for pharmacies

The National Health Surveillance Agency (Anvisa) has granted sanitary authorization for two more medicinal Cannabis products in Brazil. The new permission was granted to the company Farmausa Life Science LTDA. for the commercialization of its Cannabidiol in two different concentrations.

The decision was formalized in the Official Gazette of the Union (DOU) of this Monday (10/11), through Resolution-RE No. 4,471, of November 7, 2025. The authorized products are Cannabidiol Life Science 20 mg/mL and Cannabidiol Life Science 100 mg/mL.

Both formulations comply with the guidelines of RDC 327/2019, which establishes the criteria for the commercialization of products of this kind for medicinal purposes in the country. The authorization granted by Anvisa is specific to the formulas with tetrahydrocannabinol (THC) content of up to 0.2%.

The new cannabis-based products will be presented in oral solution, in 30 ml bottles, and come with a dosing syringe to facilitate administration to patients. According to the company, this is the first product approved in Brazil by RDC 327 that uses the active ingredient of Brazilian pharmaceutical-grade cannabidiol.